Phaseline

Companies › Sanofi

Sanofi: clinical trials, targets and expected readouts

34 active drug programs in 145 registered trials: 50 Phase 3, 42 Phase 2, 36 Phase 1, 17 Phase 4; Infectious disease, Vaccines, Metabolic and endocrine, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Ma
Recombinant spike protein vaccine with Matrix-M adjuvant targeting SARS-CoV-2 Omicron subv
–Phase 4COVID-19; Yellow Fever ImmunizationNov 2026
H5 Flu IMP 1
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1, TNFSF4, CD38, IL4RPhase 4RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic …Dec 2026
Avalglucosidase alfa (GZ402666)
Lysosomal acid alpha-glucosidase (GAA) replacement therapy
GAAPhase 4Glycogen Storage Disease Type II; Glycogen Storage Disease Type II-Pompe's Disease; Glycogen Storage Disease Type II Late OnsetJun 2027
Insulin Glargine
Insulin receptor agonist
INSRPhase 4Type 2 Diabetes (T2D); Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Type 2 Diabetes …–
rilzabrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Immune Thrombocytopenia; Sickle Cell Disease; Autoimmune Haemolytic Anaemia; Immunoglobulin G4 Related Disease …Nov 2026
SAR441344 (Frexalimab)–Phase 3Multiple Sclerosis; Systemic Lupus Erythematosus; Focal Segmental Glomerulosclerosis; Type 1 Diabetes Mellitus …Nov 2026
PCV21 vaccine
21-valent pneumococcal conjugate vaccine
–Phase 3Pneumococcal Infections; Pneumococcal ImmunizationDec 2026
Venglustat (GZ402671)
Ceramide glucosyltransferase inhibitor
UGCGPhase 3Gaucher's Disease Type III; Fabry DiseaseJan 2027
PCV21 vaccine
21-valent pneumococcal conjugate vaccine
–Phase 3Sickle Cell Disease; Pneumococcal ImmunizationJan 2027
Itepekimab (SAR440340)
Interleukin-33 inhibitor
IL33Phase 3Chronic Rhinosinusitis With Nasal PolypsFeb 2027
Lunsekimig (SAR443765)
IL-5 receptor alpha antagonist
IL5RAPhase 3Chronic Obstructive Pulmonary Disease; Asthma; Chronic Rhinosinusitis With Nasal PolypsJun 2027
Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugat
Tetanus toxoid conjugate vaccine against meningococcal serogroups A, C, W, and Y
–Phase 3Meningococcal ImmunisationDec 2027
Sarilumab (SAR153191)
Interleukin-6 receptor alpha subunit antagonist
IL6RPhase 3Polymyalgia Rheumatica; Juvenile Idiopathic Arthritis; Rheumatoid Arthritis; Melanoma …Mar 2028
MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Tox
Quadrivalent meningococcal conjugate vaccine targeting serogroups A, C, W, and Y conjugate
–Phase 3Meningococcal InfectionMar 2028
Tolebrutinib (SAR442168)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Relapsing Multiple SclerosisApr 2029
Fitusiran
Antithrombin mRNA RNAi inhibitor
SERPINC1Phase 3Hemophilia–
MenACYW conjugate vaccine (MenQuadfi)
Quadrivalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W
–Phase 3Meningococcal Infection–
SAR442970 (brivekimig)–Phase 2Ulcerative Colitis; Crohn's Disease; Focal Segmental Glomerulosclerosis; Hidradenitis Suppurativa …Dec 2026
vYF vaccine (produced on serum-free Vero cells)
Live attenuated yellow fever virus vaccine
–Phase 2Yellow Fever; Yellow Fever VaccineApr 2027
SAR447537 (INBRX-101)
Recombinant bivalent Fc fusion protein targeting alpha-1 antitrypsin deficiency
–Phase 2Alpha 1-Antitrypsin DeficiencyJun 2028
Bivalent RSV+HMPV protein vaccine (RPF08203)
Respiratory syncytial virus and human metapneumovirus protein vaccine
RSVA, RSVB, HMPVPhase 2Respiratory Syncytial VirusJul 2028
BIVV020 (SAR445088)
Neonatal Fc receptor (FcRn) antagonist
FCGRTPhase 2Transplant Rejection–
Pandemic flu H5 HA mRNA SD2 vaccine
mRNA vaccine encoding H5 hemagglutinin
HAPhase 1Pandemic Influenza ImmunizationDec 2026
Investigational hMPV/RSV vaccine
mRNA vaccine encapsulated in lipid nanoparticle targeting hMPV and RSV
HMPV, RSVPhase 1Human Metapneumovirus ImmunizationJan 2027
H5 Flu IMP 2
mRNA vaccine encoding H5 hemagglutinin antigen
–Phase 1Respiratory Syncytial Virus (RSV)Apr 2027
H5 Flu IMP 3
mRNA vaccine encoding H5 hemagglutinin antigen
–Phase 1Respiratory Syncytial Virus (RSV)Apr 2027
RSV IMP 4
mRNA vaccine encoding RSV antigen
–Phase 1Respiratory Syncytial Virus (RSV)Apr 2027
Pentavalent Meningococcal ABCYW vaccine
Conjugate vaccine against Neisseria meningitidis serogroups A, B, C, Y, and W
–Phase 1Meningococcal ImmunizationMay 2027
Pegenzileukin
IL-2R beta/gamma agonist
IL2RG, IL2RBPhase 1Plasma Cell Myeloma RefractorySep 2027
Chlamydia mRNA Vaccine
mRNA vaccine targeting Chlamydia trachomatis
–Phase 1Chlamydia Trachomatis ImmunizationNov 2027
SAR448501/DR-0201
Bispecific antibody targeting CD19 and CD3E
CD19, CD3EPhase 1B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE)Jan 2028
Flu H5 egg pandemic low dose vaccine with adjuvant Matrix-M
H5N8 influenza vaccine with Matrix-M adjuvant
–Phase 1Healthy VolunteersFeb 2028
RSV + HMPV Candidate Vaccine
Live attenuated or recombinant viral vaccine against respiratory syncytial virus and human
RSV, HMPVPhase 1Respiratory Syncytial Virus ImmunizationMay 2028
Acne mRNA vaccine
mRNA vaccine
–Phase 1AcneNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05222906Venglustat (GZ402671)Phase 3Gaucher's Disease Type IIIMetabolic and endocrineOct 2025
NCT05156710BIVV020 (SAR445088)Phase 2Transplant RejectionOtherOct 2025
NCT07135986MenACYW conjugate vaccine (MenQuadfi)Phase 3Meningococcal InfectionInfectious diseaseMay 2026
NCT07109297H5 Flu IMP 1Phase 4RSV ImmunizationVaccinesJun 2026
NCT07274644Insulin GlarginePhase 4Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic and endocrineJun 2026
NCT06637631H5 Flu IMP 1Phase 2Crohn's DiseaseImmunologyJul 2026
NCT06867094H5 Flu IMP 1Phase 2Colitis UlcerativeImmunologyAug 2026
NCT05757713H5 Flu IMP 1Phase 4Diabetes Mellitus, Type 1Metabolic and endocrineAug 2026
NCT03754790FitusiranPhase 3HemophiliaHematologySep 2026
NCT06671587Insulin GlarginePhase 4Type 2 Diabetes (T2D)Metabolic and endocrineSep 2026
NCT06033833H5 Flu IMP 1Phase 2AsthmaRespiratorySep 2026
NCT07222189H5 Flu IMP 1Phase 2Colitis UlcerativeImmunologySep 2026
NCT07646548H5 Flu IMP 1Phase 1Healthy VolunteersOtherSep 2026
NCT07855250rilzabrutinibPhase 1Healthy VolunteerOtherNov 2026
NCT05039840SAR441344 (Frexalimab)Phase 2Systemic Lupus ErythematosusImmunologyNov 2026
NCT07861542Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With MaPhase 4COVID-19Infectious diseaseNov 2026
NCT07103148Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With MaPhase 3Yellow Fever ImmunizationVaccinesNov 2026
NCT07216079rilzabrutinibPhase 3Immune ThrombocytopeniaHematologyNov 2026
NCT06838000PCV21 vaccinePhase 3Pneumococcal InfectionsInfectious diseaseDec 2026
NCT06907511Pandemic flu H5 HA mRNA SD2 vaccinePhase 1Pandemic Influenza ImmunizationVaccinesDec 2026
NCT05588843H5 Flu IMP 1Phase 2Colitis UlcerativeImmunologyDec 2026
NCT04128995Insulin GlarginePhase 4Diabetes Mellitus, Type 2Metabolic and endocrineDec 2026
NCT06975722SAR442970 (brivekimig)Phase 2Ulcerative ColitisImmunologyDec 2026
NCT06958536SAR442970 (brivekimig)Phase 2Crohn's DiseaseImmunologyDec 2026
NCT06500702rilzabrutinibPhase 2Focal Segmental GlomerulosclerosisGenitourinaryDec 2026
NCT06500702SAR442970 (brivekimig)Phase 2Focal Segmental GlomerulosclerosisGenitourinaryDec 2026
NCT06500702SAR441344 (Frexalimab)Phase 2Focal Segmental GlomerulosclerosisGenitourinaryDec 2026
NCT06619301Insulin GlarginePhase 3Diabetes Mellitus in PregnancyMetabolic and endocrineJan 2027
NCT05206773Venglustat (GZ402671)Phase 3Fabry DiseaseMetabolic and endocrineJan 2027
NCT07247188PCV21 vaccinePhase 3Sickle Cell DiseaseHematologyJan 2027
NCT06686654Investigational hMPV/RSV vaccinePhase 1Human Metapneumovirus ImmunizationInfectious diseaseJan 2027
NCT06686654Investigational hMPV/RSV vaccinePhase 1Human Metapneumovirus ImmunizationInfectious diseaseJan 2027
NCT06686654Investigational hMPV/RSV vaccinePhase 1Human Metapneumovirus ImmunizationInfectious diseaseJan 2027
NCT06686654Investigational hMPV/RSV vaccinePhase 1Human Metapneumovirus ImmunizationInfectious diseaseJan 2027
NCT05584670H5 Flu IMP 1Phase 1Solid TumorOncologyJan 2027
NCT07170917SAR442970 (brivekimig)Phase 2Hidradenitis SuppurativaImmunologyFeb 2027
NCT06984627rilzabrutinibPhase 2Graves' DiseaseMetabolic and endocrineFeb 2027
NCT07424144Itepekimab (SAR440340)Phase 3Chronic Rhinosinusitis With Nasal PolypsRespiratoryFeb 2027
NCT06834360Itepekimab (SAR440340)Phase 3Chronic Rhinosinusitis With Nasal PolypsRespiratoryFeb 2027
NCT05731128H5 Flu IMP 1Phase 2Colitis UlcerativeImmunologyFeb 2027
NCT05097287H5 Flu IMP 1Phase 4AsthmaRespiratoryMar 2027
NCT06407934H5 Flu IMP 1Phase 3Dermatitis AtopicImmunologyMar 2027
NCT05662319H5 Flu IMP 1Phase 3HemophiliaHematologyMar 2027
NCT06834347Itepekimab (SAR440340)Phase 3Chronic Rhinosinusitis With Nasal PolypsRespiratoryMar 2027
NCT06356571H5 Flu IMP 1Phase 2Plasma Cell Myeloma RefractoryOncologyApr 2027
NCT07516418H5 Flu IMP 1Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseApr 2027
NCT07516418H5 Flu IMP 2Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseApr 2027
NCT07516418H5 Flu IMP 3Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseApr 2027
NCT07516418RSV IMP 4Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseApr 2027
NCT03319667H5 Flu IMP 1Phase 3Plasma Cell MyelomaOncologyApr 2027
NCT07156175H5 Flu IMP 1Phase 2Microscopic ColitisImmunologyApr 2027
NCT07853131rilzabrutinibPhase 1Renal ImpairmentGenitourinaryApr 2027
NCT05011123vYF vaccine (produced on serum-free Vero cells)Phase 2Yellow FeverInfectious diseaseApr 2027
NCT07295028H5 Flu IMP 1Phase 1Lower Respiratory Tract DiseaseRespiratoryApr 2027
NCT06111586SAR441344 (Frexalimab)Phase 2Type 1 Diabetes MellitusMetabolic and endocrineApr 2027
NCT05983068H5 Flu IMP 1Phase 4Dermatitis AtopicImmunologyApr 2027
NCT06812988SAR442970 (brivekimig)Phase 2Type 1 Diabetes MellitusMetabolic and endocrineApr 2027
NCT04333706Sarilumab (SAR153191)Phase 1BreastOncologyMay 2027
NCT06141473SAR441344 (Frexalimab)Phase 3Multiple SclerosisNeurologyMay 2027
NCT06556147H5 Flu IMP 1Phase 1Healthy VolunteersOtherMay 2027

The 60 nearest readouts of 145 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of 8.4bn EUR on 2025-12-31; operating cash flow positive

Complete response letters from FDA

Targets

HMPV (3) BTK (2) RSV (2) FCGRT (1) CD19 (1) CD3E (1) IL33 (1) RSVA (1) RSVB (1) IL5RA (1) IL2RG (1) IL2RB (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Amgen ModernaTX Allogene Therapeutics Miltenyi Biomedicine

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.